Abstract: The present invention relates to Fms-like tyrosine kinase (FLT3) inhibitors. The present invention provides novel 4-quinolinone derivatives used as FLT3 inhibitors and for treatment and/or prevention of tumors.

Abstract: The present invention relates to Fms-like tyrosine kinase (FLT3) inhibitors. The present invention provides novel 4-quinolinone derivatives used as FLT3 inhibitors and for treatment and/or prevention of tumors.

Abstract: The present invention provides a novel series of indeno[1,2-c]quinolin-11-one derivatives and further provides their preparation methods as well as applications. Said applications includes utilizing such derivatives as pharmaceutical compositions for treating cancers; moreover, said applications includes the capability possessed by such derivatives to effectively inhibit cancer cell growth as well as the activity of Type I topoisomerases and can be further applied for cancer treatment.

Abstract: The invention provides a series of novel thiochromeno[2,3-c]quinolin-12-one derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with treating effective amount are prepared into pharmaceutical compositions for inhibition of topoisomerase type I and II, inhibition of cancer cell growth, further treating cancer.

Abstract: A heterocyclic fused anthraquinone derivative, which is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein R2 is amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.

Abstract: Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.

Abstract: A heterocyclic fused anthraquinone derivatives, which is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of hydrogen, halogens, aminoalkyl group, sulfoalkyl group, haloalkyl group, piperazino group, sulfonyl group, morpholino group, alkali group or one substituent represented by a formula (II): wherein R2 is amino group, oxyl group or a thiol group. In the meantime, a method for manufacturing the above-mentioned heterocyclic fused anthraquinone derivatives and a pharmaceutical composition using thereof are also disclosed here.

Abstract: Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.

Abstract: An air temperature exchanger installed in pipeline of cooling coil and heat dissipation coil, comprised of a cold/hot exchange baseboard with both sides respectively adapted to cooling liquid containing cold conductor and hot conductor creating a temperature difference on both sides of the base board; within, by means of a pipeline, the cold conductor, the cooling coil, the hot conductor and heat dissipation coil respectively form a closed cooling circulation pipeline and heat dissipation circulation pipeline driven by a water pump; cooling liquid in the heat dissipation pipeline flowing through the hot air conductor to dissipate heat by heat exchange on hot contact surface of the cold/hot exchange base board; consequently, a better cooling function is created on the other cold contact surface to reduce the temperature of the cooling liquid flowing through the cold conductor; and the cooling liquid in reduced temperature passes through the cooling coil to exchange temperature with and reduce the ambient tempe

Abstract: A cooling exchanger comprised of a cooling base plate, two units of water pans and two units of water pumps. Within, Said cooling base plate include two units of contact plats incorporated with multiple units of SbBi crystals and bridged with a conductor. Outer edges between said two contact plates are coated with insulation resin to close and separate a shortage. A DC source is connected to said two units of SbBi crystal containing opposite polarities connected and a relative temperature difference (&Dgr;T) takes place at where both contact plates connected to the crystals. Said two units of water pan are locked in position on two contact plates of the cooling base plate. A water inlet and a water outlet provided on the front of each eater pan are respectively connected to form a close pipeline for the water controlled by a water pump to circulate inside the pipeline.

Abstract: A cooler chip fabrication method includes the steps of (a) making an upper substrate and a bottom substrate with ceramic-resin mixture; (b) screen-printing conductor elements on the substrates; (c) adhering metal plates to the conductor elements of the substrates and then coating the conductor elements with a soldering flux; (d) adhering antimony-bismuth chips to two distal ends of each metal plate of the bottom substrate, keeping the two opposing antimony-bismuth chips of each two adjacent metal plates to show different polarity; (e) detecting and correcting the polarity of the antimony-bismuth chips; (f) fastening the upper substrate to the antimony-bismuth chips at the bottom substrate, so as to form a semi-finished cooler chip; and (g) dying antimony-bismuth chips semi-finished cooler chip into a finished cooler chip through a baking process.